Mindfulness-based Psychotherapy for Drug-resistant Epilepsy
NCT ID: NCT02060422
Last Updated: 2014-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2011-08-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The present study uses an assessor-blinded prospective randomized controlled trial to evaluate the efficacy of a mindfulness-based psychotherapy and an attentional-placebo social support on improving psychological well-being, seizure control and cognitive performance among adult patients with drug-resistant epilepsy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Mindfulness Intervention on Quality of Life in Patients With Drug-resistant Epilepsy.
NCT04126369
Mindfulness Meditation for Epilepsy
NCT04687904
A Study of Meditation as a Treatment for Epilepsy
NCT00370929
Pain and Stress Detection and Relief in People With Dementia
NCT06094400
Symptoms of Post-traumatic Stress in Adult Drug-resistant Epilepsies
NCT04749901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Social support group
Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
Social support group
Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
Mindfulness-based therapy
Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
Mindfulness-based therapy
Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mindfulness-based therapy
Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
Social support group
Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* over 18 years of age
* resistant to pharmacological treatment according to the ILAE guideline
* no previous history of neurosurgery
* adequate level of reading and understanding ability to fill in questionnaires
* capable to communicate with the investigator with considerable expressive capacity
* patients who agree to cooperate with the study procedures required by the protocol
* patients who understand the nature of the study, agree to participate and sign the informed consent form
Exclusion Criteria
* with diagnosis of learning disability or mental retardation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Venus Tang
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Venus Tang, PhD
Role: PRINCIPAL_INVESTIGATOR
Division of Neurosurgery, Faculty of Medicine, CUHK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CUHK Division of Neurosurgery, Faculty of Medicine
Hong Kong, Hong Kong, Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRE-2011.167-T
Identifier Type: OTHER
Identifier Source: secondary_id
VP-2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.